Clinical Trials
AstraZeneca Provides Update on Phase III Trial of Selumetinib in Non-Small Cell Lung Cancer
AstraZeneca announced results from the Phase III SELECT-1 trial of the MEK 1/2 inhibitor, selumetinib, in combination with docetaxel chemotherapy as 2nd-line treatment in patients with KRAS mutation-positive (KRASm) locally-advanced or metastatic non-small cell lung cancer (NSCLC). ...
Clinical Trials
Antibe Therapeutics Announces Successful Phase 2 Trial Of ATB-346 In Osteoarthritis
Antibe Therapeutics Inc. is pleased to announce the successful completion of its phase 2 clinical trial of ATB-346 in osteoarthritis (“OA”). Twelve patients with OA of the knee were treated once daily for 10 days with ATB-346 at a...
Clinical Trials
ClinicalRM And Mapp Biopharmaceutical Combine Efforts To Continue The Fight Against Ebola
ClinicalRM will again deploy its boots-on-the-ground approach to fighting Ebola Virus Disease (EVD) with an expanded access protocol for ZMappTM, an investigational treatment for EVD, in Africa and the U.S. ClinicalRM will perform as subcontractor under...
Clinical Trials
Inovio Pharmaceuticals Doses First Subject in Zika Vaccine Clinical Trial
Inovio Pharmaceuticals, Inc announced the dosing of the first subject in its multi-center phase I trial to evaluate Inovio’s Zika DNA vaccine (GLS-5700). In addition to the previously announced US FDA approval for the conduct of the study, Health...
Clinical Trials
Positive VIMPAT monotherapy Phase III trial results presented at European Academy of Neurology Congress
Trial further highlights UCB’s longstanding commitment to enhancing value for people living with epilepsy Data submitted to EMA earlier this year to extend the marketing authorization for lacosamide to include monotherapy. In the Europe, lacosamide is currently only...
Clinical Trials
Merck Announces Results From Phase 3 Studies of ZEPATIER™ in Chronic Hepatitis C Patient Populations at The International Liver Congress™
Merck, known as MSD outside of the United States and Canada, today announced the presentation of results from two Phase 3 clinical trials evaluating ZEPATIER™ (elbasvir and grazoprevir) 50mg/100mg tablets in chronic hepatitis C (HCV) patients with inherited blood...
Clinical Trials
First-in-Human Clinical Trial for New Molecular Targeting Drug, Co-Developed with The University of Tokyo and National Cancer Center
The National Cancer Center, The University of Tokyo, and Daiichi Sankyo Company, Limited announced a collaboration to develop a histone methylation enzyme EZH1/2 dual inhibitor (DS-3201), as a new molecular targeting agent for hematologic malignancy, and the commencement of...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
